Crossref

1. The diverse landscape of dermatologic toxicities of non‐immune checkpoint inhibitor monoclonal antibody‐based cancer therapy

- Riyad N. H. Seervai

- Sarah K. Friske

- Emily Y. Chu

- Rhea Phillips

- Kelly C. Nelson

- Auris Huen

- Woo Cheal Cho

- Phyu P. Aung

- Carlos A. Torres‐Cabala

- Victor G. Prieto

- Jonathan L. Curry

2. Tebentafusp: The First FDA-approved Monoclonal Antibody for Cancer Treatment in 2022

- Pouya Safarzadeh Kozani

- Pooria Safarzadeh Kozani

- Abdolkarim Sheikhi

3. CD99 tumor associated antigen is a potential target for antibody therapy of T-cell acute lymphoblastic leukemia

- Kamonporn Kotemul

- Watchara Kasinrerk

- Nuchjira Takheaw